Mark R. Sotir
Known title: DirectorCIK: 0001397283
Associated companies
Transaction History
| ARDT | ▲ Buy | Grant | 14,231 | $0 | 4/1/2026 | View on chart |
| ARDT | ▲ Buy | Grant | 12,916 | $0 | 3/21/2025 | View on chart |
| ARDT | ▲ Buy | Grant | 11,562 | $0 | 7/18/2024 | View on chart |
| ARDT | ▲ Buy | Grant | 14,231 | $0 | 4/1/2026 | View on chart |
| ARDT | ▲ Buy | Grant | 12,916 | $0 | 3/21/2025 | View on chart |
| ARDT | ▲ Buy | Grant | 11,562 | $0 | 7/18/2024 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
ARDT Schedules Q3 2026 Results Call and Webcast
Ardent Health announced the date for its third quarter 2026 earnings conference call and webcast. The call will provide management’s discussion of the latest financial results and operational updates. Investors often use such events to assess performance trends, especially as the stock currently shows strong momentum on the chart.
ARDT Schedules Q3 2026 Results Call and Webcast. Ardent Health announced the date for its third quarter 2026 earnings conference call and webcast. The call will provide management’s discussion of the latest financial results and operational updates. Investors often use such events to assess performance trends, especially as the stock currently shows strong momentum on the chart.